Peculiarities of hemostasisin transurethral resection of prostatic gland using fybrinolysis inhibitor

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Urothelial cancer, in 90 % cases presented as bladder cancer, is the most common malignant neoplasm in urinary tract. Organ-sparing treatment for non-muscle invasive bladder cancer, combined with chemotherapy and immunotherapy, is a standard method, in muscle-invasive tumors radical surgical treatment in combination with chemotherapy is applied. Various prognostic criteria are under investigation now.

Full Text

Restricted Access

About the authors

Igor Alekseevich Korneyev

St.-Petersburg State Medical University named after acad. I. P. Pavlov

Email: iakorneyev@yandex.ru
doctor of medical science, professor. Department of Urology.

Yuriy Andreevich Sukhanov

St.-Petersburg State Medical University named after acad. I. P. Pavlov

Email: j.sukhanov@yandex.ru
MD. Department of Urology. St.-Petersburg State Medical University named after acad. I. P. Pavlov

References

  1. Аль-Шукри С. Х., Ткачук В. Н. Опухоли мочеполовых органов. СПб.: Питер, 2000. C. 86–134.
  2. Лопаткин Н. А. Урология. Национальное руководство. М.: ГЭОТАР-Медиа. 2009. C. 821–837.
  3. Bagley D. H., Grasso M., 3rd. Ureteroscopic laser treatment of upper urinary tract neoplasms // World J Urol. 2010.Vol. 28, № 2. P. 143–149.
  4. Brausi M., Collette L., Kurth K. et al. EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta–T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies // Eur Urol. 2002. Vol. 41, № 5. P. 523–531.
  5. Chade D. C., Laudone V. P., Bochner B. H. et al. Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches // J Urol. 2010. Vol. 183, № 3. P. 862–869.
  6. Fernando S. A., Sandler H. M. Organ preservation in muscle-invasive bladder cancer // Oncology (Huntingt). 2005. Vol.19. P. 334–339.
  7. Gadzinski A. J., Roberts W. W., Faerber G. J. et al. Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma // J Urol. 2010. Vol.183, № 6. P. 2148–2153.
  8. Ghoneim M. A., Abdel-Latif M., El-Mekresh M., et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 year later // J Urol. 2008. Vol. 180, № 1. P. 121–127.
  9. Hautmann R. E., Abol-Enein H., Hafez K. et al. Urinary diversion. World Health Organization (WHO) Consensus Conference in Bladder Cancer, // Urology. 2007. Vol. 69, № 1 Suppl. P. 17–49.
  10. Herr H. W. Conservative management of muscle-infiltrating bladder cancer: prospective experience // J Urol. 1987. Vol. 138, № 5. P.1162–1163.
  11. Herr H. W., Bochner B. H., Dalbagni G. et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer // J Urol. 2002. Vol. 167, № 3. P. 1295–1298.
  12. Joudi F. N., Smith B. J., O’Donnell M. A. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer // Urol Oncol. 2006. Vol. 24, № 4. P. 344–8.
  13. Kaufman D. S., Winter K. A., Shipley W. U. et al. Phase I–II RTOG study (99–06) of patients with muscleinvasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy // Urology. 2009. Vol. 73, № 4. P. 833–837.
  14. Kurth K. H., Denis L., Bouffioux Ch. et al. Factors affecting recurrence and progression in superficial bladder tumors // Eur Jour Cancer. 1995. Vol. 31A, № 11. P. 1840–1846.
  15. Margulis V., Shariat S. F., Matin S. F. et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration // Cancer. 2009. Vol. 115, № 6. P.1224–33.
  16. Millan-Rodrigeguez F., Chechile-Tonio G., Salvador Bayarri J. et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence // J Urol. 2000. 164. P. 680–684
  17. Pagano F., Bassi P., Ferrante G. L. et al. Is pT4a (D1) stage reliable in assessing transitional cell carcinoma involvement of the prostate in patients with concurrent bladder bladder cancer? // Eur Urol. 1996. Vol. 45. P. 465–470
  18. Piet A. H., Hulshof M. C., Pieters B. R. et al. Clinical Results of a concomitant boost radiotherapy technique for muscle-invasive bladder cancer // Strahlenther Onkol. 2008. Vol. 184, № 6. P. 313–8.
  19. Pos F., Horenblas S., Dom P. et al. Organ preservation in invasive bladder cancer: Brachytherapy, an alternative to cystectomy and combined modality treatment? // Int J Radiat Oncol Biol Phys. 2005. Vol. 61. P. 678–686.
  20. Pycha A., Mian C., Hofbauer J. et al. Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer? // J Urol. 1998. Vol. 159, № 1. P. 265–269.
  21. Van Rhijn B. W., Zuiverloon T. C., Vis A. N. et al. Molecular grade (FGFR3 / MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer // Eur Urol. 2010. Vol. 58, № 3. P. 433–441.
  22. Rouprкt M., Hupertan V., Sanderson K, M. et al. Oncologic control after open or laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: a single center experience // Urology. 2007. Vol. 69, № 4. P. 656–661.3. Bagley D. H., Grasso M., 3rd. Ureteroscopic laser treatment of upper urinary tract neoplasms // World J Urol. 2010. Vol. 28, № 2. P. 143–149.
  23. Slack N. H., Bross I. D., Prout G. R. Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder // J Surg Oncol. 1977. Vol. 9. P. 393–405.
  24. Sylvester R. J., Oosterlinck W., van der Meijden A. P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta–T1 bladder cancer: a metaanalysis of published results of randomized clinical trials // J Urol. 2004. Vol. 171. P. 2186–2190.
  25. Sylvester R. J., van der Meijden A. P., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials // Eur Urol. 2006. Vol. 49, № 3. P. 466–475.
  26. Sylvester R. J., van der Meijden A. P., Lamm D. L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta analysis of the published results of randomized clinical trials // J Urol. 2002. Vol. 168, № 5. P. 1964–70
  27. Van der Meijden A. P. M., Sylvester R., Oosterlinck W. et al. for the EAU Working Party on Non Muscle Invasive Bladder Cancer. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ // Eur Urol. 2005. Vol. 48, № 3. P. 363–371.
  28. Vale C. L. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta analysis collaboration // Eur Urol. 2005. Vol. 48, № 2. P. 202–205.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Korneyev I.A., Sukhanov Y.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ №ФС77-65570 от 04 мая 2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies